“And given the ramp of our oral CGRPs, we believe our migraine franchise will also exceed $5 billion in peak sales.”

In context

“next wave of RINVOQ indications. You know, we have a lot of confidence in the long-term potential for those two assets. But beyond immunology, when you look at AbbVie, I think what's underappreciated is both, I'd say, neuroscience and oncology in particular. I'd say neuroscience is clearly overperforming. We delivered nearly 20% growth last year. We expect to deliver mid-teens growth this year. It'll put us in the number one position in the industry. I mean, Violet will already achieve our peak sales guidance this year. We had given long-term guidance of greater than a billion dollars peak. We're guiding to a billion dollars. We think our Parkinson's franchise, including BioLeb, Duopa, and Tivapadon, can achieve peak sales in excess of $5 billion. That's not reflected in treatment models. And given the ramp of our oral CGRPs, we believe our migraine franchise will also exceed $5 billion in peak sales. Recall, we gave peak sales estimates of greater than $3 billion based on this year's guidance, we're almost there. And so, clearly, the street is not modeling that type of upside for our migraine business. In psychiatry, we have several next-generation assets with 962, bradisilacin as Roopal highlighted, and emriclidine, which we're clearly studying the dose. That can help replace the $5 billion peak of Vraylar at its LOE in 2030. So we're in a very strong position to lead in neuroscience for the long term with three $5 billion-plus franchises. And I haven't even mentioned essential tremor or other therapeutic toxin indications, or the opportunity in Alzheimer's. And so, you know, we have, I'd say, a profound opportunity to lead in neuroscience for the long term, and that's clearly not re”